Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CAEL-101 (birtamimab) for safety and tolerability in patients with AL amyloidosis has completed. Results were posted on March 5, 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• CAEL-101 (birtamimab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: AL Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2025-03-05